Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurogen (NRGN) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (199)	2/2/1999 3:53:00 PM
From: Ritchmc	Respond to of 523

You're right- real ugly.

To: scaram(o)uche who wrote (199)	2/2/1999 6:58:00 PM
From: NeuroInvestment	Read Replies (1) \| Respond to of 523

There was a time (95/96) that I printed criticism of NRGN for giving away its future pipeline in exchange for industry-standard royalties. I was wrong. Given the stunning and seemingly unremitting series of failures in schizophrenia, anxiety, obesity, and epilepsy--if it was not for the cash and cachet that NRGN acquired, primarily from Pfizer, the company would be now at risk of delisting from NASDAQ. It is a humbling scenario--in spite of their technical expertise-- for no one knows more about the GABA-A receptor than they do, and they have the receptor clone that should allow the rational design of effective subtype-specific modulators--the depth of their portfolio has been essentially defined by the replacement molecules they can rally to supplant the failed ones. It is also a message to Big Pharma companies now increasingly convinced that their genomics/high throughput screening capabilities will generate all the molecule candidates they need; that translating that specificity into clinical efficacy seems to be more difficult than thought--especially by companies, big or small, as completely convinced of their superiority as has been Neurogen. NeuroInvestment (www.neuroinvestment.com)